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Recently, the development of the fluorinated PET tracer [18F]1a for imaging of CB2 
receptors in the central nervous system was reported. [18F]1a showed high CB2 affinity 
and selectivity over the CB1 subtype, but rapid biotransformation in mice. In addition to 
the amide hydrolysis, oxidative N-dealkylation and carbazole oxidation were postulated 
as main metabolic pathways. Based on these results, novel carbazole derivatives with 
additional 6-substituents (23a, 24a), modified hydrogenation state (26a) and enlarged 
fluoroalkyl substituent (13a, 13b) were synthesized and pharmacologically evaluated. 
The key step in the synthesis of substituted carbazoles 23a, 24a and 26a was a Fischer 
indole synthesis. Nucleophilic substitution of tosylated lactate 5 by carbazole anion 
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provided the fluoroisopropyl derivatives 13a and 13b. Partial hydrogenation of the 
aromatic carbazole system (26a) was not tolerated by the CB2 receptor. A 
methylsulfonyl moiety in 6-position (24a) led to considerably reduced CB2 affinity, 
whereas a 6-methoxy moiety (23a) was well tolerated. An additional methyl moiety in 
the fluoroethyl side chain of 1a resulted in fluoroisopropyl derivatives 13 with 
unchanged high CB2 affinity and CB2 : CB1 selectivity. Compared with the fluoroethyl 
derivative 1a, the carbazole N-atom of the fluoroisopropyl derivative 13a (Ki(CB2) = 
2.9 nM) is better shielded against the attack of CYP enzymes as formation of N-oxides 
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The first medical use of Cannabis sativa L. for the treatment of rheumatic pain, 
constipation and malaria, as well as the toxic effects, were reported in one of the oldest 
pharmacopeia, the pen-ts’ao ching [1]. It is assumed that this book was written in the 
first century A.D. based on oral traditions from the years around 2700 B.C. [2]. 
However, cannabis did not find a broad medical application in the western world until 
the midst 19th century, as reflected by the first medical conference on Cannabis in 
1860, organized by the Ohio State Medical Society. The preliminary peak of the 
medical use was reached at the end of the 19th century, however, in the first decades 
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of the 20th century, the use decreased again due to political reasons and the 
development of new synthetic drugs such as acetylsalicylic acid and barbiturates [2].  
In 1964, the isolation and characterization of Δ9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) stimulated the discovery of the endogenous cannabinoid 
(endocannabinoid) system in the following decades. After cloning of the cannabinoid 
receptor subtypes CB1 [3] and CB2 [4] in the early 1990s, it was possible to develop 
selective compounds for CB1 and CB2 receptors, respectively. Both CB receptor 
subtypes belong to the class of Gi/o protein-coupled receptors (GPCR) and show an 
amino acid sequence homology of 44 % [5], but differ primarily in their expression 
pattern. The CB1 receptor is one of the most common GPCR of the central nervous 
system (CNS) and is present in all four brain regions (cerebrum, diencephalon, 
cerebellum, brainstem) [6]. In these regions the CB1 receptor plays an important 
modulating role for the release of other excitatory and inhibitory neurotransmitters (e.g. 
GABA) [7], especially in the synapses of neurons. The psychoactive side effects of 
THC, such as dysphoria and concentration disorders, are also attributed to activation 
of the CB1 receptor. 
In contrast, the expression of the CB2 receptor in the CNS under normal conditions is 
rather low. However, the expression of the CB2 receptor can be increased up to 100-
fold under inflammatory conditions (neuroinflammation) [8]. In many test systems, it 
could be shown that activation of the CB2 receptor reduces the release of numerous 
inflammatory mediators, such as IL-1, IL-6 and tumor necrosis factor α (TNF α), as well 
as increases the release of anti-inflammatory factors (e.g. IL-10), thus resulting in an 
overall anti-inflammatory effect [9]. Therefore, the CB2 receptor is regarded as a 
potential target for drugs directed for the treatement of many neuroimmunological and 
neurodegenerative diseases including depression, schizophrenia, Alzheimer's 
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disease, multiple sclerosis, amyotrophic lateral sclerosis, down syndrome, and 
Huntington's disease [9],[10],[11],[12],[13]. 
The positron emission tomography (PET) is an imaging modality that enables 
visualization and quantification of receptors under healthy and pathological conditions. 
The site of bound radiochemically labeled compound is visualized in vivo by the 
simultaneous detection of two gamma photons. The preferably used radioisotope is 
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Figure 1. Postulated biotransformation of [18F]1a. 
 
In 2013, we described the synthesis, radiosynthesis and biological evaluation of the 
CB2 receptor PET tracer [18F]1a containing a (phenyl-oxadiazolyl)propionamide 
scaffold [15],[16]. The ligand showed a high CB2 affinity (Ki (hCB2) = 2.3 nM), excellent 
selectivity over the CB1 receptor (ca. 500-fold), penetration into the brain and low 
tendency to loose [18F]fluoride in vivo. On the other hand, 1a showed some 
disadvantages like a rapid metabolism and relatively high lipophilicity (logD7.4 = 3.82 – 
4.21, recorded by HPLC). During in vivo experiments, a very polar radiometabolite was 
detected by radio-HPLC. It was postulated that [18F]fluoroacetic acid [18F]3 was formed 
by oxidative cleavage of the [18F]fluoroethyl moiety at the carbazole system (Figure 1). 
In this work, we aim to synthesize fluorinated CB2 receptor ligands with a sterically 
more demanding fluoroisopropyl residue in 9-position of the carbazole system to inhibit 
oxidative degradation by CYP enzymes. Moreover, different substituents in 6-position 
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of the carbazole scaffold of 1a should be introduced to inhibit metabolic oxidation at 6-









7, R = CH2OH, 65 %
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10, Y = NO2
, 87 %









13a, X = Br, 70 % 























12b, X = Cl
 
Scheme 1. Reagents and reaction conditions: (a) 1. NaH, DMF, rt  110 °C; 2. LiAlH4, 
THF, rt  reflux. (b) tosyl chloride, NEt3, pyridine, CH2Cl2, rt. (c) TBAF·3H2O, 60 °C. 
(d) HNO3 65 %, CH2Cl2, 0 °C. (e) 1. H2, Pd/C 10 %, THF, 1 bar, rt; 2. HCl in Et2O. (f) 
COMU®, EtNiPr2, THF, rt. 
 
For the synthesis of CB2 ligands 13 with fluoroisopropyl side chain racemic, methyl 
lactate 4 was tosylated [17] and the product 6 was reacted with deprotonated carbazole 
5. Subsequent reduction of the ester with LiAlH4 afforded alcohol 7 in 65 % yield. 
Treatment of 7 with tosyl chloride under basic conditions yielded tosylate 8, which was 
reacted with TBAF·3H2O in a nucleophilic substitution under solvent-free conditions. 
Fluoroisopropylcarbazole 9 was nitrated with nitric acid 65 % at 0 °C. Hydrogenation 
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of 10 catalyzed by Pd/C provided the primary aromatic amine 11, which was 
precipitated as HCl salt 11∙HCl. In the last step, carbazolamine·HCl 11∙HCl was 
acylated with carboxylic acids 12a and 12b in the presence of COMU® to yield amides 
13a and 13b (Scheme 1). The 1,2,4-oxadiazol building blocks 11 and 12 were obtained 
by NH2OH addition to 2-bromo- and 2-chloro-4-fluorobenzonitrile followed by acylation 
with succinic anhydride [15], [18], [19]. 
The Craig plot [20] was used for the selection of suitable substituents in 6-position. A 
methoxy group was selected as an electron-donating substituent and a methylsulfonyl 
moiety as a polar electron-withdrawing substituent. Moreover, the two substituents are 































14 15, R = OCH3, 97 %
16, R = SO2CH3, 79 %
17, 53 %
19, R = OCH3, 83 %
20, R = SO2CH3, 61 %
21·HCl, R = OCH3, 52 %























23a, R = OCH3, 33 %





Scheme 2. Reagents and reaction conditions: (a) 4-methoxyphenylhydrazine 
hydrochloride, EtOH, reflux. (b) 4-(methylsulfonyl)phenylhydrazine, AcOH, reflux. (c) 
NaH, DMF, TsOCH2CH2F, 0 °C  95 °C. (d) DDQ, THF, reflux. (e) Cs2CO3, DMF, 
TsOCH2CH2F, 0 °C  rt. (f) 1. 19, H2N-NH2·H2O, EtOH, reflux; 2. HCl in Et2O. (g) 1. 
20, H2N-NH2·H2O, EtOH, CH2Cl2, 40 °C; 2. HCl in Et2O. (h) 12a, COMU®, EtNiPr2, 
THF, rt. 
 
To obtain carbazoles with a substituent in 6-position, 4-methoxy- and 4-
(methylsulfonyl)phenylhydrazine were reacted with cyclohexanone derivative 14 in a 
Fischer indole synthesis [21]. The required 4-methylsulfonylphenylhydrazine was 
synthesized by nucleophilic aromatic substitution of 4-chlorophenyl methyl sulfone with 
hydrazine according to the literature [22]. Tetrahydrocarbazole 15 was alkylated with 
fluoroethyl tosylate and DDQ was used for the oxidation to afford the carbazole 19. For 
the synthesis of carbazole 20 the aromatization was carried out first and afterwards 
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the fluoroethyl moiety was introduced using Cs2CO3 instead of NaH. Hydrazinolysis of 
the phthalimides 19 and 20 led to the primary amines 21 and 22, which were acylated 



















Scheme 3. Reagents and reaction conditions: (a) 1. H2N-NH2·H2O, EtOH, reflux; 2. 
HCl in Et2O. (b) 12a, COMU®, EtNiPr2, THF, rt. 
 
Furthermore, the tetrahydrocarbazole 26a was synthesized to determine the effects of 
the less planar scaffold on CB2 affinity. Therefore, tetrahydrocarbazole 17 was 
subjected to hydrazinolysis and 25∙HCl was coupled with propionic acid 12a to yield 




3. Receptor affinity 
Table 1. CB1 and CB2 receptor affinity of fluorosiopropyl derivatives 13, compounds 23 




















13,23a,24a 26a  
compd R1 R2 X Ki (hCB2) 
± SEM [nM]a) 
displacement 
(hCB1)b) 
1a H H Br 2.9 ± 0.4 22 %c) 
13a CH3 H Br 2.9 ± 0.4 12 % 
13b CH3 H Cl 1.5 ± 0.1 10 % 
23a H OCH3 Br 56 ± 7 3 % 
24a H SO2CH3 Br 1137 ± 124 8 % 
26a 1 %b) 10 % 
CP 55,940 8.4 ± 0.2 9.3 ± 0.1 
WIN 55,212-2 8.6 ± 0.2 8.7 ± 0.2 
HU 210 9.8 ± 0.04 9.6 ± 0.1 
a) The reported Ki-values are mean values of three independent experiments (n = 3). 
b) Due to the low hCB1 affinity, only the radioligand displacement at a test compound 
concentration of 1 µM is given. Mean value of two independent experiments (n = 2). 
c) Mean value of four experiments (n = 4). 
 
The fluoroisopropyl derivatives 13a and 13b show similar high CB2 affinity as the 
fluoroethyl derivative 1a. Also, the affinity of both compounds to the CB1 receptor is 
very low indicating high selectivity over the CB1 receptor. 
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Compared to a proton, the 6-methoxy group of 23a has a similar polarity, but is 
sterically more demanding, possesses an additional H-bond acceptor and increases 
the electron density of the carbazole system. With a Ki value of 56 nM, the CB2 affinity 
of 23a is by 19-fold decreased compared to the lead compound 1a. In contrast, the 
methylsulfonyl group is a very polar substituent, possesses two additional H-bond 
acceptors, decreases the electron density in the carbazole system and is sterically 
much more demanding than a proton. Compared to the lead compound 1a, the CB2 
affinity of sulfone 24a is 400-fold decreased. 
Due to the sp3-hybridized C-atoms in 1- to 4-position, tetrahydrocarbazole 26a is no 
longer planar, which is not tolerated by the CB2 receptor. At a test compound 
concentration of 1 μM, the tetrahydrocarbazole 26a could only displace 1 % of the 
radioligand. Obviously, the Ki value is greater than 1 μM. 
 
4. Metabolism studies of 13a 
In vivo studies of [18F]1a in mice revealed low metabolic stability as only 35 % of intact 
radiotracer [18F]1a were detected 60 min after injection [15]. Furthermore, the in vitro 
stability over time was determined by incubation with mouse liver microsomes and 
metabolite structures were identified in our lab using LC-MS-MS [23]. After an 
incubation time of 90 min, 69.8 ± 0.5 % (SEM) of 1a remained intact. The hydrolysis of 
the amide bond was identified as major clearance pathway, which was also reported 
and described in in vivo experiments with rats and mice [15], [19]. In addition, the 
oxidative N-dealkylation of the carbazole-N-atom 1a was postulated, resulting in a loss 
of the F-atom of the potential positron emitter. Therefore, the effect of an additional 
methyl moiety in α-position to the tertiary amine (13a) on the metabolism was 
investigated. 
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Fluoroisopropylcarbazole 13a was incubated with mouse liver microsomes or mouse 
plasma. The resulting samples were analyzed using LC-qToF-MS, which allowed 

































































































Figure 2. Proposed structures of metabolites identified 90 min after incubation of 13a 
with mouse liver microsomes and NADPH. * The marked metabolites were also formed 
without NADPH and in murine blood serum. 
 
In total, ten metabolites of compound 13a were detected (Figure 2). Oxidative N-
dealkylation led to metabolite 13a-A, and following amide-hydrolysis to primary 
aromatic amine 13a-B. This metabolite could also be formed by hydrolysis of the parent 
compound 13a and subsequent N-dealkylation of 13a-C. Two additional primary 
aromatic amines 13a-D and 13a-E resulted from hydroxylation of 13a-C. The exact 
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position of the OH moiety at the carbazole ring of metabolite 13a-D is unknown. 
However, the 6-position is most likely bearing the hydroxy moiety. Moreover, the two 
metabolites 13a-F and 13a-G, hydroxylated in the fluoroisopropyl side chain, could be 
detected (tR = 11.82 min and 12.14 min), which possess almost the same 
fragmentation pattern (see supporting information, chapter 2). Therefore, it is 
assumed, that the hydroxy groups are attached to the terminal alkyl moieties of the 
isopropyl side chain, since a hydroxy moiety at the C-atom in the middle would lead to 
an unstable hemiaminal. Metabolite 13a-H was obtained by defluorination. Although 
this metabolite was formed in minor amounts, the F-atom of the potential positron 
emitter is lost. In contrast to the identified metabolites of 1a [23], formation of a 
carbazole N-oxide was not observed. It is assumed that the sterically demanding 
fluoroisopropyl moiety is shielding the carbazole N-atom from oxidative attack by CYP 
enzymes. The fragmentation pattern of metabolite 13a-I bearing the OH moiety at the 
trimethylene spacer connecting the carbazole and 1,2,4-oxadiazole rings is given in 
Figure 3.  
Since fragmentation of metabolite 13a-I led to a carbazole fragment (m/z 243.1305) 
without OH-moiety, which is formed by cleavage of the amide bond, hydroxylation of 
the carbazole and fluoroisopropyl substructures was excluded. (Figure 3) Fragment 
m/z 285.9750 proved hydroxylation of the phenyloxadiazolylpropyl part of the 
molecule. Furthermore, fragment m/z 214.9611 with a diazirine ring excluded 
hydroxylation of the phenyl ring, and thus confirmed the position of the OH group in 
the trimethylene linker. Diazirine derivatives, resulting from 1,2,4-oxadiazole 
fragmentation under electron impact ionization conditions, have already been 































Figure 3. Fragmentation of metabolite 13a-I. 
 
In order to show the effect of the additional methyl moiety of the fluoroisopropyl 
derivative 13a on oxidative N-dealkylation the fluoroethyl and fluoroisopropyl 
derivatives 1a and 13a were incubated under the same conditions with mouse liver 
microsome preparations and NADPH. The extracted ion chromatograms (EICs) of the 
resulting N-unsubstituted carbazole 13a-A (= 1a-A) are compared in Figure 4. 
According to the EICs, the additional methyl moiety reduced oxidative N-dealkylation 
of 13a approximately by two-thirds after 90 min in comparison with the oxidative N-
dealkylation of the fluoroethyl moiety. 
14 
 
Figure 4. EICs m/z 479.0513 for the incubations of 1a and 13a with mouse liver 
microsomes and NADPH. The left blue peak resulted from the in-source fragmentation 
of metabolite 1a-K [23]. 
 
5. Conclusion 
In order to inhibit N-dealkylation and oxidation of the N-substituted carbazole moiety of 
the potent CB2 agonist 1a (Ki (hCB2) = 2.9 nM) novel ligands with a modified carbazole 
substitution pattern were synthesized. The key step of the synthesis of CB2 ligands 
with modified substituents in 6-position or with a partly hydrogenated carbazole 
scaffold was a Fischer indole synthesis with N-protected 4-aminocyclohexanone 14 
and substituted phenylhydrazines. Whereas a methylsulfonyl moiety in 6-position of 
the carbazole system (24a) was not tolerated by the CB2 receptor, the methoxy 
derivative 23a showed considerable CB2 affinity (Ki = 56 nM). Partial hydrogenation of 
the carbazole to form a tetrahydrocarbazole system (26a) led to complete loss of CB2 
affinity indicating that a planar aromatic ring system is essential to achieve strong 
interactions with the CB2 receptor. Introduction of an additional methyl moiety into the 
fluoroethyl side chain of 1a resulted in the fluoroisopropyl derivatives 13a 
(Ki (hCB2) = 2.9 nM) and 13b (Ki (hCB2) = 1.5 nM) with almost the same CB2 affinity 
and selectivity over the CB1 subtype. Investigation of the in vitro metabolism of the 
fluoroisopropyl derivative 13a with murine microsomes and subsequent LC-MS-MS 
analysis revealed ten metabolites in small amounts. In comparison to 1a [23], formation 
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of an N-oxide was not observed and the extent of oxidative N-dealkylation was reduced 
to one third. In can be concluded that the additional methyl moiety of the fluoroisopropyl 
derivatives 13 does not reduce CB2 affinity, but is able to shield the carbazole N-atom 
from oxidative attack by microsomal CYP enzymes. Thus, the fluoroisopropyl moiety 
represents a promising substituent for the development of carbazole-based PET 
tracers for the selective imaging of CB2 receptors in the CNS. 
 
6. Experimental 
6.1 Chemistry, General Methods 
Oxygen and moisture sensitive reactions were carried out under nitrogen, dried with 
silica gel with moisture indicator (orange gel, Merck) and in dry glassware (Schlenk 
flask or Schlenk tube). Temperatures were controlled with dry ice/acetone (-78 °C), 
ice/water (0 °C), Cryostat (Julabo FT 901 or Huber TC100E-F), magnetic stirrer MR 
3001 K (Heidolph) or RCT CL (IKA®), together with temperature controller EKT HeiCon 
(Heidolph) or VT-5 (VWR) and PEG or silicone bath. All solvents were of analytical 
grade quality. Demineralized water was used. THF was distilled from 
sodium/benzophenone. Methanol was distilled from magnesium methanolate. CH3CN 
and ethanol abs. were dried with molecular sieves (3 Å); DMF, ethyl acetate and 
toluene were dried with molecular sieves (4 Å). Thin layer chromatography (tlc): tlc 
silica gel 60 F254 on aluminum sheets (Merck). Flash chromatography (fc): Silica gel 
60, 40–63 µm (Merck); parentheses include: diameter of the column (∅), length of the 
stationary phase (l), fraction size (v) and eluent. Melting point: Melting point system 
MP50 (Mettler Toledo), open capillary, uncorrected. MS: MicroTOFQII mass 
spectrometer (Bruker Daltonics); deviations of the found exact masses from the 
calculated exact masses were 5 ppm or less; the data were analyzed with 
DataAnalysis (Bruker). NMR: NMR spectra were recorded on Agilent DD2 400 MHz 
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and 600 MHz spectrometers; chemical shifts (δ) are reported in parts per million (ppm) 
against the reference substance tetramethylsilane and calculated using the solvent 
residual peak of the undeuterated solvent. IR: FT/IR IRAffinity-1 IR spectrometer 
(Shimadzu) using ATR technique. 
 
6.2 HPLC method for the determination of the purity 
Equipment 1: Pump: L-7100, degasser: L-7614, autosampler: L-7200, UV detector: L-
7400, interface: D-7000, data transfer: D-line, data acquisition: HSM-Software (all from 
LaChrom, Merck Hitachi); Equipment 2: Pump: LPG-3400SD, degasser: DG-1210, 
autosampler: ACC-3000T, UV-detector: VWD-3400RS, interface: DIONEX UltiMate 
3000, data acquisition: Chromeleon 7 (Thermo Fisher Scientific); column: LiChropher® 
60 RP-select B (5 µm), LiChroCART® 250-4 mm cartridge; flow rate: 1.0 mL/min; 
injection volume: 5.0 µL; detection at λ = 210 nm; solvents: A: demineralized water with 
0.05 % (V/V) trifluoroacetic acid, B: acetonitrile with 0.05 % (V/V) trifluoroacetic acid; 
gradient elution (% A): 0 - 4 min: 90 %; 4 - 29 min: gradient from 90 % to 0 %; 
29 - 31 min: 0 %; 31 - 31.5min: gradient from 0 % to 90 %; 31.5 - 40 min: 90 %. 
 
6.3 Synthetic procedures 
6.3.1 2-(Carbazol-9-yl)propan-1-ol (7) [25] 
Preparation of this compound is described in the literature [25] following a different 
synthesis route. 
Under N2 atmosphere, carbazole (5, 1.79 g, 11 mmol, 1 eq.) was dissolved in dry DMF 
(54 mL). NaH (60 % dispersion in Paraffin Oil, 0.99 g, 25 mmol, 2.3 eq.) was added 
and the mixture was stirred for 30 min. After the dropwise addition of tosylate 6 (6.38 g, 
25 mmol, 2.3 eq.), the reaction mixture was stirred at 110 °C for 43 h. Water (10 mL) 
and a saturated Na2CO3 solution (40 mL) were added and the mixture was extracted 
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with ethyl acetate (200 mL). The organic layer was washed with water (2 x 50 mL) and 
brine (50 mL), dried (Na2SO4) and concentrated under reduced pressure. LiAlH4 
(1.63 g, 42 mmol, 4 eq.) was suspended in dry THF (130 mL) and the ester dissolved 
in THF (20 mL) was added over 15 min. The mixture was heated at reflux for 16 h 
before it was quenched with a NaOH solution (1M, 10 mL) and water (40 mL). Insoluble 
impurities were removed by filtration and washed with ethyl acetate (200 mL). The 
organic layer was separated from the aqueous layer and washed with brine (50 mL). 
Afterwards, the ethyl acetate layer was dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by fc with a gradient (∅ = 5 cm, l = 18 cm, 
v = 60 mL, cyclohexane/ethyl acetate 85:15, 70:30, Rf = 0.35 (cyclohexane/ethyl 
acetate 7:3)). Beige solid, mp 117 °C, yield 1.56 g (65 %). Purity (HPLC): 98.6 % 
(tR = 20.4 min). C15H15NO (225.3 g/mol). Exact mass (APCI): m/z = 226.1224 (calcd. 
226.1226 for C15H16NO [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 1.59 (d, J 
= 7.2 Hz, 3H, CH3), 3.85 - 3.90 (m, 1H, CH2OH), 4.00 - 4.06 (m, 1H, CH2OH), 
4.88 - 4.95 (m, 2H, NCH, CH2OH), 7.17 (t, J = 7.4 Hz, 2H, 3-H, 6-H), 7.40 (t, J = 7.7 
Hz, 2H, 2-H, 7-H), 7.65 (d, J = 8.3 Hz, 2H, 1-H, 8-H), 8.14 (d, J = 7.7 Hz, 2H, 4-H, 5-
H). 13C NMR (151 MHz, DMSO-D6): δ (ppm) = 15.8 (1C, CH3), 53.3 (1C, NCH), 63.3 
(1C, CH2OH), 111.1 (2C, C-1, C-8), 118.8 (2C, C-3, C-6), 120.5 (2C, C-4, C-5), 123.0 
(2C, C-4a, C-4b), 125.8 (2C, C-2, C-7), 140.1 (2C, C-8a, C-9a). FTIR (neat): ṽ (cm-1) 
= 3325 (m, O-H), 3062 (w, C-H, arom), 2877 (w, C-H, aliph), 1593 (s, C-C, arom). 
 
 
6.3.2 2-(Carbazol-9-yl)propyl 4-methylbenzenesulfonate (8) 
Under N2 atmosphere, tosyl chloride (2.55 g, 13 mmol, 2 eq.) was dissolved in dry 
CH2Cl2 (30 mL), dry pyridine (10 mL) and triethylamine (1.4 mL, 10 mmol, 1.5 eq.). 
Carbazole derivative 7 (1.50 g, 6.7 mmol, 1 eq.) dissolved in dry CH2Cl2 (10 mL) was 
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added dropwise over 10 min. The reaction mixture was stirred at room temperature for 
17 h followed by evaporation to dryness in vacuo. The residue was dissolved in HCl 
(1 M, 20 mL) and the solvent was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were washed with a saturated Na2CO3 solution (20 mL), which was 
extracted with CH2Cl2 (2 x 20 mL). After drying (Na2SO4), the combined CH2Cl2 layers 
were concentrated under reduced pressure. The residue was purified by fc (∅ = 4 cm, 
l = 18 cm, v = 30 mL, cyclohexane/ethyl acetate 90:10, Rf = 0.39 (cyclohexane/ethyl 
acetate 8:2)). Colorless solid, mp 93 °C, yield 2.14 g (84 %). Purity (HPLC): 99.7 % 
(tR = 24.5 min). C22H21NO3S (379.5 g/mol). Exact mass (APCI): m/z = 380.1310 (calcd. 
380.1315 for C22H22NO3S [M+H+]). 1H NMR (400 MHz, DMSO-D6): δ (ppm) = 1.57 (d, 
J = 7.2 Hz, 3H, CHCH3), 2.29 (s, 3H, Ar-CH3), 4.45 (dd, J = 10.7/4.1 Hz, 1H, CH2), 4.70 
(dd, J = 10.7/9.6 Hz, 1H, CH2), 5.18 - 5.25 (m, 1H, NCH), 7.03 (d, J = 8.4 Hz, 2H, 3-
Hphenyl, 5-Hphenyl), 7.18 (t, J = 7.5 Hz, 2H, 3-Hcarb, 6-Hcarb), 7.21 (d, J = 8.3 Hz, 2H, 2-
Hphenyl, 6-Hphenyl), 7.34 (t, J = 7.6 Hz, 2H, 2-Hcarb, 7-Hcarb), 7.51 (d, J = 8.3 Hz, 2H, 1-
Hcarb, 8-Hcarb), 8.11 (d, J = 7.7 Hz, 2H, 4-Hcarb, 5-Hcarb). 13C NMR (101 MHz, DMSO-
D6): δ (ppm) = 14.7 (1C, CHCH3), 21.1 (1C, Ar-CH3), 49.2 (1C, NCH), 70.4 (1C, CH2), 
110.2 (2C, C-1carb, C-8carb), 118.8 (2C, C-3carb, C-6carb), 120.1 (2C, C-4carb, C-5carb), 
122.6 (2C, C-4acarb, C-4bcarb), 125.5 (2C, C-2carb, C-7carb), 126.8 (2C, C-2phenyl, C-
6phenyl), 129.6 (2C, C-3phenyl, C-5phenyl), 131.3 (1C, C-1phenyl), 139.0 (2C, C-8acarb, C-
9acarb), 144.5 (1C, C-4phenyl). FTIR (neat): ṽ (cm-1) = 2943 (w, C-H, aliph), 1597 (w, C-
C, arom), 1354 (s, SO3), 1165 (s, SO3). 
 
6.3.3 9-(1-Fluoropropan-2-yl)carbazole (9) 
TBAF·3H2O (2.71 g, 8.6 mmol, 2.2 eq.) was added to tosylate 8 (1.48 g, 3.9 mmol, 
1 eq.) and the mixture was stirred at 60 °C for 23 h. After addition of ethyl acetate 
(80 mL), the organic layer was washed with water (2 x 40 mL) and brine (40 mL), dried 
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(Na2SO4) and concentrated in vacuo. The residue was purified by fc (∅ = 4 cm, 
l = 16 cm, v = 30 mL, cyclohexane/ethyl acetate 99:1, Rf = 0.65 (cyclohexane/ethyl 
acetate 8:2)). Colorless solid, mp 82 - 83 °C, yield 0.472 g (53 %). Purity (HPLC): 
96.4 % (tR = 23.0 min). C15H14FN (227.3 g/mol). Exact mass (APCI): m/z = 228.1185 
(calcd. 228.1183 for C15H15FN [M+H+]). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.78 
(dd, J = 7.2/1.5 Hz, 3H, CH3), 4.84 (ddd, J = 33.2/9.0/5.8 Hz, 1H, CH2F), 4.96 (ddd, J 
= 33.7/9.0/5.8 Hz, 1H, CH2F), 5.05 - 5.19 (m, 1H, NCH), 7.25 (ddd, J = 7.9/6.9/1.2 Hz, 
2H, 3-H, 6-H), 7.45 (ddd, J = 8.3/6.9/1.2 Hz, 2H, 2-H, 7-H), 7.49 (dt, J = 8.2/1.0 Hz, 
2H, 1-H, 8-H), 8.11 (dt, J = 7.8/0.9 Hz, 2H, 4-H, 5-H). 13C NMR (101 MHz, CDCl3): δ 
(ppm) = 14.9 (d, J = 5.0 Hz, CH3), 50.9 (d, J = 21.8 Hz, 1C, NCH), 84.3 (d, J = 175.0 
Hz, 1C, CH2F), 109.9 (2C, C-1, C-8), 119.3 (2C, C-3, C-6), 120.5 (2C, C-4, C-5), 123.7 
(2C, C-4a, C-4b), 125.8 (2C, C-2, C-7), 139.8 (2C, C-8a, C-9a). FTIR (neat): ṽ (cm-1) 
= 3059 (w, C-H, arom), 2951 (w, C-H, aliph), 1593 (m, C-C, arom). 
 
6.3.4 9-(1-Fluoropropan-2-yl)-3-nitrocarbazole (10) 
Fluoroisopropylcarbazole 9 (0.537 g, 2.4 mmol, 1 eq.) was dissolved in CH2Cl2 (12 mL) 
and cooled down to 0 °C. HNO3 65 % (250 µL, 3.6 mmol, 1.5 eq.) was added and the 
solution was stirred at 0 °C for 4 h. Afterwards, the reaction mixture was diluted with 
water (5 mL), neutralized with a saturated NaHCO3 solution and the aqueous layer was 
diluted with water to 10 mL. After evaporation of CH2Cl2 in vacuo, the aqueous layer 
was extracted with ethyl acetate (1 x 20 mL, 2 x 10 mL). The combined organic layers 
were dried (Na2SO4) and the solvent was evaporated in vacuo. The residue was 
purified by fc (∅ = 3 cm, l = 15 cm, v = 20 mL, cyclohexane/ethyl acetate 30:70, 
Rf = 0.60 (cyclohexane/ethyl acetate 6:4)). Yellow solid, mp 192 - 193 °C, yield 0.561 g 
(87 %). Purity (HPLC): 98.6 % (tR = 22.6 min). C15H13FN2O2 (272.3 g/mol). Exact mass 
(APCI): m/z = 273.1047 (calcd. 273.1034 for C15H14FN2O2 [M+H+]). 1H NMR (400 MHz, 
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DMSO-D6): δ (ppm) = 1.67 (dd, J = 7.2/0.9 Hz, 3H, CH3), 4.86 (ddd, J = 45.7/10.0/4.2 
Hz, 1H, CH2F), 5.08 (ddd, J = 48.3/9.8/8.7 Hz, 1H, CH2F), 5.34 - 5.52 (m, 1H, NCH), 
7.32 - 7.37 (m, 1H, 6-H), 7.56 (ddd, J = 8.4/7.2/1.3 Hz, 1H, 7-H), 7.85 (d, J = 8.4 Hz, 
1H, 8-H), 7.91 (d, J = 9.2 Hz, 1H, 1-H), 8.31 (dd, J = 9.2/2.4 Hz, 1H, 2-H), 8.43 (d, J = 
7.8 Hz, 1H, 5-H), 9.18 (d, J = 2.2 Hz, 1H, 4-H). 13C NMR (151 MHz, DMSO-D6): δ 
(ppm) = 13.9 (d, J = 6.9 Hz, 1C, CH3), 51.1 (d, J = 19.3 Hz, 1C, NCH), 83.6 (d, J = 
170.5 Hz, 1C, CH2F), 110.7 (1C, C-1), 111.6 (1C, C-8), 117.1 (1C, C-4), 120.7 (1C, C-
6), 121.1 (1C, C-2), 121.5 (1C, C-5), 122.5 (1C, C-4a), 122.7 (1C, C-4b), 127.4 (1C, 
C-7), 140.1 (1C, C-3), 140.7 (1C, C-8a), 143.0 (1C, C-9a). FTIR (neat): ṽ (cm-1) = 2966 
(w, C-H, aliph), 1593 (w, C-C, arom), 1508 (m, C-C, arom), 1315 (s, NO2). 
 
6.3.5 9-(1-Fluoropropan-2-yl)carbazol-3-ammonium chloride (11·HCl) 
Under N2 atmosphere, nitrocarbazole 10 (0.528 g, 1.9 mmol, 1 eq.) was dissolved in 
dry THF (52 mL). Pd/C 10 % (80 mg) was added and the mixture was stirred for 24 h 
under H2 atmosphere (balloon). After filtration through Celite®, the mixture was 
concentrated under reduced pressure and the residue was dissolved in Et2O. A 
solution of HCl in Et2O (2 M, 1.0 mL, 2.0 mmol, 1.03 eq.) was added dropwise until the 
salt 11·HCl precipitated completely. The precipitate was filtered off, washed with cold 
Et2O and dried under reduced pressure. Rf = 0.52 (cyclohexane/ethyl acetate 3:7). 
Grey solid, mp 220 - 240 °C (decomposition), yield 0.492 g (91 %). Purity (HPLC): 
97.9 % (tR = 15.4 min). C15H16ClFN2 (278.8 g/mol). Exact mass (APCI): m/z = 
243.1283 (calcd. 243.1292 for C15H16FN2 [M+H+]). 1H NMR (400 MHz, DMSO-D6): δ 
(ppm) = 1.64 (d, J = 6.9 Hz, 3H, CH3), 4.84 (ddd, J = 45.8/9.9/4.4 Hz, 1H, CH2F), 5.05 
(dt, J = 48.3/9.1 Hz, 1H, CH2F), 5.27 - 5.43 (m, 1H, NCH), 7.25 (t, J = 7.4 Hz, 1H, 6-
H), 7.41 - 7.56 (m, 2H, 2-H, 7-H), 7.77 (d, J = 8.3 Hz, 1H, 8-H), 7.84 (d, J = 8.8 Hz, 1H, 
1-H), 8.15 (d, J = 2.2 Hz, 1H, 4-H), 8.20 (d, J = 7.7 Hz, 1H, 5-H), 10.45 (s, 3H, -NH3+). 
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13C NMR (101 MHz, DMSO-D6): δ (ppm) = 13.9 (d, J = 6.9 Hz, 1C, CH3), 50.5 (d, J = 
19.4 Hz, 1C, NCH), 83.6 (d, J = 170.4 Hz, 1C, CH2F), 110.9 (1C, C-8), 111.4 (1C, C-
1), 114.7 (1C, C-4), 119.4 (1C, C-6), 120.5 (1C, C-5), 120.6 (1C, C-2), 121.9 (1C, C-
4b), 122.8 (1C, C-4a), 123.1 (1C, C-3), 126.5 (1C, C-7), 138.5 (1C, C-9a), 140.1 (1C, 




Under N2 atmosphere, N-ethyl-N,N-diisopropylamine (0.14 mL, 0.83 mmol, 3 eq.) and 
COMU® (155 mg, 0.36 mmol, 1.3 eq.) were added to a solution of carboxylic acid 12a 
(96 mg, 0.31 mmol, 1.1 eq.) in dry THF (3 mL). After the reaction mixture had been 
stirred at room temperature for 50 min, carbazolamine hydrochloride 11·HCl (78 mg, 
0.28 mmol, 1 eq.) was added and stirring was continued for 24 h. Afterwards, all 
volatiles were removed under reduced pressure and the residue was dissolved in ethyl 
acetate (30 mL). The organic solvent was washed with water (2 x 10 mL) and brine 
(50 mL). After drying (Na2SO4), the organic layer was concentrated in vacuo. The 
residue was purified by fc with a gradient (∅ = 2 cm, l = 15 cm, v = 10 mL, 
cyclohexane/ethyl acetate/triethylamine 70:30:1, 65:35:1, Rf = 0.64 (cyclohexane/ethyl 
acetate 4:6)). Yellowish solid, mp 147 - 148 °C, yield 105 mg (70 %). Purity (HPLC): 
96.5 % (tR = 23.8 min). C26H21BrF2N4O2 (539.4 g/mol). Exact mass (APCI): m/z = 
539.0895 (calcd. 539.0889 for C26H2279BrF2N4O2 [M+H+]). 1H NMR (400 MHz, DMSO-
D6): δ (ppm) = 1.61 (d, J = 6.4 Hz, 3H, CH3), 2.99 (t, J = 6.9 Hz, 2H, CH2CH2CONH), 
3.36 (t, J = 7.0 Hz, 2H, CH2CH2CONH), 4.82 (ddd, J = 46.0/9.7/4.4 Hz, 1H, CH2F), 
5.02 (dt, J = 48.2/9.0 Hz, 1H, CH2F), 5.16 - 5.34 (m, 1H, NCH), 7.17 (t, J = 7.4 Hz, 1H, 
6-Hcarb), 7.36 - 7.48 (m, 2H, 7-Hcarb, 5-Hphenyl), 7.51 (dd, J = 8.9/1.9 Hz, 1H, 2-Hcarb), 
7.65 (d, J = 8.7 Hz, 1H, 1-Hcarb), 7.68 (d, J = 8.5 Hz, 1H, 8-Hcarb), 7.82 (dd, J = 8.6/2.5 
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Hz, 1H, 3-Hphenyl), 7.88 (dd, J = 8.7/6.1 Hz, 1H, 6-Hphenyl), 8.04 (d, J = 7.6 Hz, 1H, 5-
Hcarb), 8.41 (d, J = 1.7 Hz, 1H, 4-Hcarb), 10.15 (s, 1H, CONH). 13C NMR (151 MHz, 
DMSO-D6): δ (ppm) = 14.0 (d, J = 6.8 Hz, 1C, CH3), 21.8 (1C, CH2CH2CONH), 32.0 
(1C, CH2CH2CONH), 50.3 (d, J = 19.6 Hz, 1C, NCH), 83.7 (d, J = 170.4 Hz, 1C, CH2F), 
110.5 (2C, C-1carb, C-8carb), 110.8 (1C, C-4carb), 115.5 (d, J = 21.6 Hz, 1C, C-5phenyl), 
118.7 (1C, C-2carb), 118.7 (1C, C-6carb), 120.0 (1C, C-5carb), 121.4 (d, J = 25.1 Hz, 1C, 
C-3phenyl), 122.1 (d, J = 10.2 Hz, 1C, C-2phenyl), 122.4 (2C, C-4acarb, C-4bcarb), 124.4 (d, 
J = 3.5 Hz, 1C, C-1phenyl), 125.7 (1C, C-7carb), 131.2 (1C, C-3carb), 133.6 (d, J = 9.4 Hz, 
1C, C-6phenyl), 135.9 (1C, C-9acarb), 140.0 (1C, C-8acarb), 162.8 (d, J = 253.2 Hz, 1C, C-
4phenyl), 166.6 (1C, C-3oxadiazole), 168.5 (1C, C=O), 179.6 (1C, C-5oxadiazole). FTIR (neat): 
ṽ (cm-1) = 3279 (w, NH), 2924 (w, C-H, aliph), 1643 (m, C=O), 1593 (m, C-C, arom), 




Under N2 atmosphere, N-ethyl-N,N-diisopropylamine (0.16 mL, 0.91 mmol, 3 eq.) and 
COMU® (169 mg, 0.39 mmol, 1.3 eq.) were added to a solution of carboxylic acid 12b 
(90 mg, 0.33 mmol, 1.1 eq.) in dry THF (3 mL). After the reaction mixture had been 
stirred at room temperature for 30 min, carbazolamine hydrochloride 11·HCl (85 mg, 
0.30 mmol, 1 eq.) was added and stirring was continued for 24 h. Afterwards, all 
volatiles were removed under reduced pressure and the residue was dissolved in ethyl 
acetate (30 mL). The organic layer was washed with NaOH solution (1 M, 10 mL), 
water (10 mL) and brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The 
residue was purified by fc (∅ = 2 cm, l = 15 cm, v = 10 mL, cyclohexane/ethyl acetate 
70:30, Rf = 0.64 (cyclohexane/ethyl acetate 4:6)). Beige solid, mp 157 - 159 °C, yield 
88 mg (59 %). Purity (HPLC): 98.2 % (tR = 23.3 min). C26H21ClF2N4O2 (494.9 g/mol). 
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Exact mass (APCI): m/z = 495.1393 (calcd. 495.1394 for C26H2235ClF2N4O2 [M+H+]). 
1H NMR (600 MHz, DMSO-D6): δ (ppm) = 1.61 (d, J = 6.9 Hz, 3H, CH3), 3.00 (t, J = 
6.9 Hz, 2H, CH2CH2CONH), 3.36 (t, J = 6.9 Hz, 2H, CH2CH2CONH), 4.81 (ddd, J = 
45.9/9.8/4.4 Hz, 1H, CH2F), 5.02 (dt, J = 48.1/9.0 Hz, 1H, CH2F), 5.19 - 5.30 (m, 1H, 
NCH), 7.17 (t, J = 7.4 Hz, 1H, 6-Hcarb), 7.38 - 7.44 (m, 2H, 3-Hphenyl, 7-Hcarb), 7.51 (dd, 
J = 8.8/1.6 Hz, 1H, 2-Hcarb), 7.63 - 7.70 (m, 3H, 1-Hcarb, 8-Hcarb, 5-Hphenyl), 7.97 (dd, J = 
8.6/6.2 Hz, 1H, 6-Hphenyl), 8.04 (d, J = 7.7 Hz, 1H, 5-Hcarb), 8.41 (d, J = 1.3 Hz, 1H, 4-
Hcarb), 10.15 (s, 1H, CONH). 13C NMR (151 MHz, DMSO-D6): δ (ppm) = 14.0 (d, J = 
6.7 Hz, 1C, CH3), 21.8 (1C, CH2CH2CONH), 32.0 (1C, CH2CH2CONH), 50.3 (d, J = 
19.6 Hz, 1C, NCH), 83.7 (d, J = 170.4 Hz, 1C, CH2F), 110.5 (2C, C-1carb, C-8carb), 110.8 
(1C, C-4carb), 115.2 (d, J = 21.7 Hz, 1C, C-3phenyl), 118.4 (d, J = 25.5 Hz, 1C, C-5phenyl), 
118.7 (1C, C-2carb), 118.7 (1C, C-6carb), 120.0 (1C, C-5carb), 122.3 (d, J = 3.4 Hz, 1C, 
C-1phenyl), 122.4 (2C, C-4acarb, C-4bcarb), 125.7 (1C, C-7carb), 131.2 (1C, C-3carb), 133.4 
(d, J = 9.7 Hz, 1C, C-6phenyl), 133.5 (d, J = 11.1 Hz, 1C, C-2phenyl), 135.9 (1C, C-9acarb), 
139.9 (1C, C-8acarb), 163.0 (d, J = 252.5 Hz, 1C, C-4phenyl), 165.7 (1C, C-3oxadiazole), 
168.6 (1C, C=O), 179.6 (1C, C-5oxadiazole). FTIR (neat): ṽ (cm-1) = 3282 (w, NH), 2927 
(w, C-H, aliph), 1639 (m, C=O), 1593 (m, C-C, arom), 1550 (m, C-C, arom). 
 
6.3.8 N-(6-Methoxy-1,2,3,4-tetrahydrocarbazol-3-yl)phthalimide (15) [21] 
A solution of N-(4-oxocyclohexyl)phthalimide (14, 5.00 g, 21 mmol, 1 eq.) and 4-
methoxyphenylhydrazine hydrochloride (3.59 g, 21 mmol, 1 eq.) in dry ethanol 
(100 mL) was heated at reflux for 2.5 h. After cooling down to room temperature, the 
precipitate was filtrated off and washed with ethanol 96 % (3 x 10 mL). The solid was 
dried under reduced pressure and freeze-dried overnight. Rf = 0.66 (cyclohexane/ethyl 
acetate/dimethylethylamine 5:5:0.2). Colorless solid, mp 222 - 223 °C, yield 6.88 g 
(97 %). Purity (HPLC): 84.1 % (tR = 22.2 min). C21H18N2O3 (346.4 g/mol). Exact mass 
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(APCI): m/z = 347.1389 (calcd. 347.1390 for C21H19N2O3 [M+H+]). 1H NMR (400 MHz, 
DMSO-D6): δ (ppm) = 2.03 - 2.11 (m, 1H, 2-H), 2.67 (tt, J = 12.3/ 6.4 Hz, 1H, 2-H), 
2.80 - 2.98 (m, 3H, 1-CH2, 4-H), 3.20 - 3.28 (m, 1H, 4-H), 3.71 (s, 3H, OCH3), 
4.43 - 4.52 (m, 1H, 3-H), 6.65 (dd, J = 8.7/2.4 Hz, 1H, 7-H), 6.82 (d, J = 2.4 Hz, 1H, 5-
H), 7.15 (d, J = 8.7 Hz, 1H, 8-H), 7.84 - 7.91 (m, 4H, 4-Hphth, 5-Hphth, 6-Hphth, 7-Hphth), 
10.61 (s, 1H, NH). 13C NMR (101 MHz, DMSO-D6): δ (ppm) = 22.6 (1C, C-1), 24.7 (1C, 
C-4), 26.5 (1C, C-2), 47.8 (1C, C-3), 55.3 (1C, OCH3), 99.7 (1C, C-5), 106.3 (1C, C-
4a), 109.9 (1C, C-7), 111.2 (1C, C-8), 123.0 (2C, C-4phth, C-7phth), 127.2 (1C, C-4b), 
131.3 (1C, C-8a), 131.5 (2C, C-3aphth, C-7aphth), 134.2 (1C, C-9a), 134.4 (2C, C-5phth, 
C-6phth), 153.0 (1C, C-6), 167.9 (2C, C=O). FTIR (neat): ṽ (cm-1) = 3425 (w, N-H), 3379 
(w, C-H, arom), 2924 (w, C-H, aliph), 1697 (s, C=O), 1597 (w, C-C, arom). 
 
6.3.9 N-[6-(Methylsulfonyl)-1,2,3,4-tetrahydrocarbazol-3-yl]phthalimide (16) 
A solution of N-(4-oxocyclohexyl)phthalimide (14, 3.53 g, 15 mmol, 1 eq.) and 
4-(methylsulfonyl)phenylhydrazine (2.70 g, 15 mmol, 1 eq.) in glacial acetic acid 
(110 mL) was heated at reflux for 47 h. The mixture was concentrated in vacuo and 
the residue was dissolved in CH2Cl2 (200 mL). Afterwards, the organic layer was 
washed with water (2 x 70 mL) and brine (70 mL), dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by fc with a gradient (∅ = 6 cm, 
l = 13 cm, v = 60 mL, cyclohexane/CH2Cl2 60:40, 50:50, 30:70, 0:100, 
CH2Cl2/methanol 100:10, Rf = 0.51 (cyclohexane/ethyl acetate/formic acid 3:7:0.2)). 
Pale yellow solid, mp 282 - 284 °C, yield 4.50 g (79 %). Purity (HPLC): 86.6 % 
(tR = 19.6 min). C21H18N2O4S (394.5 g/mol). Exact mass (APCI): m/z = 395.1072 
(calcd. 395.1060 for C21H19N2O4S [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 
2.11 (d, J = 12.3 Hz, 1H, 2-H), 2.64 - 2.74 (m, 1H, 2-H), 2.92 - 3.01 (m, 3H, 1-CH2, 4-
H), 3.12 (s, 3H, CH3), 3.29 - 3.33 (m, 1H, 4-H), 4.47 - 4.54 (m, 1H, 3-H), 7.49 (d, J = 
25 
8.6 Hz, 1H, 8-H), 7.56 (dd, J = 8.6/1.4 Hz, 1H, 7-H), 7.84 - 7.93 (m, 5H, 5-H, 4-Hphth, 
5-Hphth, 6-Hphth, 7-Hphth), 11.45 (s, 1H, NH). 13C NMR (151 MHz, DMSO-D6): δ (ppm) = 
22.5 (1C, C-1), 24.2 (1C, C-4), 26.2 (1C, C-2), 44.6 (1C, CH3), 47.4 (1C, C-3), 108.3 
(1C, C-4a), 111.2 (1C, C-8), 117.3 (1C, C-5), 118.9 (1C, C-7), 123.0 (2C, C-4phth, C-
7phth), 126.3 (1C, C-4b), 130.7 (1C, C-6), 131.5 (2C, C-3aphth, C-7aphth), 134.5 (2C, C-
5phth, C-6phth), 136.8 (1C, C-9a), 138.5 (1C, C-8a), 167.9 (2C, C=O). FTIR (neat): ṽ (cm-





Under N2 atmosphere, tetrahydrocarbazole 15 (3.00 g, 8.7 mmol, 1 eq.) was dissolved 
in dry DMF (43 mL) and NaH (60 % dispersion in Paraffin Oil, 0.866 g, 18 mmol, 
2.5 eq.) was added at 0 °C. After stirring at 0 °C for 30 min, fluoroethyl tosylate (2.46 g, 
11 mmol, 1.3 eq.) was added slowly to the reaction mixture. The mixture was heated 
at 95 °C for 2.5 h. Water (5 mL) was added, the reaction mixture was concentrated in 
vacuo and the residue was dissolved in ethyl acetate (300 mL). The organic layer was 
washed with saturated Na2CO3 solution (2 x 100 mL) and water (100 mL), dried 
(Na2SO4) and concentrated under reduced pressure. Rf = 0.67 (cyclohexane/ethyl 
acetate/dimethylethylamine 6:4:0.2). Pale yellow solid, mp 150 -190 °C 
(decomposition), yield 1.81 g (53 %). Purity (HPLC): 99.2 % (tR = 23.3 min). 
C23H21FN2O3 (392.4 g/mol). Exact mass (APCI): m/z = 393.1606 (calcd. 393.1609 for 
C23H22FN2O3 [M+H+]). 1H NMR (400 MHz, DMSO-D6): δ (ppm) = 2.08 - 2.18 (m, 1H, 
2-H), 2.66 (tt, J = 12.2/ 7.2 Hz, 1H, 2-H), 2.81 - 3.01 (m, 3H, 1-CH2, 4-H), 3.25 (t, J = 
13.0 Hz, 1H, 4-H), 3.72 (s, 3H, OCH3), 4.31 - 4.51 (m, 3H, CH2CH2F, 3-H), 4.65 (dt, J 
= 47.5/4.3 Hz, 2H, CH2F), 6.72 (dd, J = 8.8/2.2 Hz, 1H, 7-H), 6.86 (d, J = 2.1 Hz, 1H, 
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5-H), 7.31 (d, J = 8.8 Hz, 1H, 8-H), 7.83 - 7.93 (m, 4H, 4-Hphth, 5-Hphth, 6-Hphth, 7-Hphth). 
13C NMR (101 MHz, DMSO-D6): δ (ppm) = 21.5 (1C, C-1), 24.6 (1C, C-4), 26.3 (1C, 
C-2), 43.0 (d, J = 20.3 Hz, 1C, CH2CH2F), 47.6 (1C, C-3), 55.3 (1C, OCH3), 82.9 (d, J 
= 167.5 Hz, 1C, CH2F), 99.9 (1C, C-5), 106.6 (1C, C-4a), 110.1 (2C, C-7, C-8), 123.0 
(2C, C-4phth, C-7phth), 126.8 (1C, C-4b), 131.5 (2C, C-3aphth, C-7aphth), 131.7 (1C, C-
8a), 134.5 (2C, C-5phth, C-6phth), 135.2 (1C, C-9a), 153.4 (1C, C-6), 167.9 (2C, C=O). 
FTIR (neat): ṽ (cm-1) = 2931 (w, C-H, aliph), 1701 (s, C=O), 1589 (w, C-C, arom). 
 
6.3.11 N-[6-(Methylsulfonyl)carbazol-3-yl]phthalimide (18) 
Tetrahydrocarbazole 16 (2.00 g, 5.1 mmol, 1 eq.) was dissolved in THF (40 mL) and 
DDQ (2.88 g, 13 mmol, 2.5 eq.) was added to the solution. The reaction mixture was 
heated at reflux for 3 h. After removing the solvent under reduced pressure, the residue 
was filtered, washed with water (350 mL), dried under reduced pressure and freeze-
dried overnight. Rf = 0.45 (cyclohexane/ethyl acetate/formic acid 4:6:0.2). Pale yellow 
solid, mp > 300 °C, yield 1.75 g (88 %). Purity (HPLC): 75.9 % (tR = 18.7 min). 
C21H14N2O4S (390.4 g/mol). Exact mass (APCI): m/z = 391.0735 (calcd. 391.0747 for 
C21H15N2O4S [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 3.24 (s, 3H, CH3), 
7.55 (dd, J = 8.5/1.9 Hz, 1H, 2-H), 7.72 (d, J = 8.5 Hz, 1H, 1-H), 7.75 (d, J = 8.6 Hz, 
1H, 8-H), 7.93 - 7.95 (m, 3H, 7-H, 5-Hphth, 6-Hphth), 8.00 - 8.02 (m, 2H, 4-Hphth, 7-Hphth), 
8.37 (d, J = 1.7 Hz, 1H, 4-H), 8.74 (d, J = 1.8 Hz, 1H, 5-H), 12.09 (s, 1H, NH). 13C NMR 
(151 MHz, DMSO-D6): δ (ppm) = 44.5 (1C, CH3), 111.8 (1C, C-1), 111.8 (1C, C-8), 
120.5 (1C, C-4), 120.6 (1C, C-5), 121.9 (1C, C-4b), 122.1 (1C, C-3), 123.4 (2C, C-4phth, 
C-7phth), 124.0 (1C, C-4a), 124.5 (1C, C-7), 126.6 (1C, C-2), 131.2 (1C, C-6), 131.6 
(2C, C-3aphth, C-7aphth), 134.8 (2C, C-5phth, C-6phth), 140.0 (1C, C-9a), 142.7 (1C, C-
8a), 167.6 (2C, C=O). FTIR (neat): ṽ (cm-1) = 3352 (m, N-H), 2920 (w, C-H, aliph), 1705 
(s, C=O), 1604 (w, C-C, arom), 1134 (s, SO2). 
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6.3.12 N-[9-(2-Fluoroethyl)-6-methoxycarbazol-3-yl]phthalimide (19) 
Tetrahydrocarbazole 17 (1.40 g, 3.6 mmol, 1 eq.) was dissolved in THF (28 mL) and 
DDQ (2.02 g, 8.9 mmol, 2.5 eq.) was added to the solution. The reaction mixture was 
heated at reflux for 2 h. After evaporation of the solvent under reduced pressure, the 
residue was filtered and washed with ethyl acetate (250 mL) and CH2Cl2 (70 mL). The 
solvents were evaporated under reduced pressure and the residue was dissolved in 
CH2Cl2 (200 mL). Afterwards, the organic layer was washed with a saturated Na2CO3 
solution (70 mL), a saturated NH4Cl solution (70 mL), water (2 x 70 mL) and brine 
(70 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The resulting product was used without further purification. Rf = 0.44 
(cyclohexane/ethyl acetate/dimethylethylamine 5:5:0.2). Dark yellow solid, mp 222 °C, 
yield 1.15 g (83 %). C23H17FN2O3 (388.4 g/mol). Compound was purified by fc with a 
gradient (∅ = 2 cm, l = 14 cm, v = 10 mL, cyclohexane/ethyl 
acetate/dimethylethylamine 80:20:1, 75:25:1, 60:40:1) leading to a purity (HPLC) of 
96.9 % (tR = 21.4 min). Exact mass (APCI): m/z = 389.1284 (calcd. 389.1296 for 
C23H18FN2O3 [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 3.85 (s, 3H, OCH3), 
4.72 - 4.86 (m, 4H, CH2CH2F), 7.14 (dd, J = 8.9/2.5 Hz, 1H, 7-H), 7.46 (dd, J = 8.7/2.0 
Hz, 1H, 2-H), 7.60 (d, J = 8.9 Hz, 1H, 8-H), 7.71 (d, J = 8.7 Hz, 1H, 1-H), 7.73 (d, J = 
2.4 Hz, 1H, 5-H), 7.91 - 7.95 (m, 2H, 5-Hphth, 6-Hphth), 7.98 - 8.02 (m, 2H, 4-Hphth, 7-
Hphth), 8.20 (d, J = 1.9 Hz, 1H, 4-H). 13C NMR (151 MHz, DMSO-D6): δ (ppm) = 43.1 
(d, J = 20.1 Hz, 1C, CH2CH2F), 55.6 (1C, OCH3), 82.7 (d, J = 167.7 Hz, 1C, CH2F), 
103.2 (1C, C-5), 109.7 (1C, C-1), 110.7 (1C, C-8), 115.4 (1C, C-7), 119.9 (1C, C-4), 
122.1 (1C, C-4a), 122.3 (1C, C-4b), 122.7 (1C, C-3), 123.4 (2C, C-4phth, C-7phth), 125.2 
(1C, C-2), 131.6 (2C, C-3aphth, C-7aphth), 134.7 (2C, C-5phth, C-6phth), 135.6 (1C, C-8a), 
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140.1 (1C, C-9a), 153.6 (1C, C-6), 167.7 (2C, C=O). FTIR (neat): ṽ (cm-1) = 2924 (w, 
C-H, aliph), 1716 (s, C=O). 
 
6.3.13 N-[9-(2-Fluoroethyl)-6-(methylsulfonyl)carbazol-3-yl]phthalimide (20) 
Under N2 atmosphere, carbazole derivative 18 (1.10 g, 2.8 mmol, 1 eq.) was dissolved 
in dry DMF (25 mL). Cs2CO3 (1.84 g, 5.6 mmol, 2 eq.) was added at 0 °C. After stirring 
at 0 °C for 30 min, fluoroethyl tosylate (0.738 g, 3.4 mmol, 1.2 eq.) was added slowly 
to the reaction mixture. Stirring was continued for 18 h at room temperature. 
Afterwards, the solvent was removed in vacuo, the residue was dissolved in CH2Cl2 
(200 mL) and the solution was washed with water (3 x 60 mL). The organic layer was 
dried (Na2SO4) and concentrated in vacuo. The residue was purified by fc with a 
gradient (∅ = 3 cm, l = 20 cm, v = 30 mL, cyclohexane/CH2Cl2 60:40, 50:50, 30:70, 
15:85, 0:100, CH2Cl2/methanol 100:0.5, cyclohexane/CH2Cl2/ 
dimethylethylamine 30:70:1, 15:85:0, Rf = 0.60 (cyclohexane/ethyl acetate/ 
dimethylethylamine 1:9:0.2)). Pale yellow solid, mp 289 - 292 °C, yield 0.756 g (61 %). 
Purity (HPLC): 96.0 % (tR = 20.0 min). C23H17FN2O4S (436.5 g/mol). Exact mass 
(APCI): m/z = 437.0965 (calcd. 437.0966 for C23H18FN2O4S [M+H+]). 1H NMR (400 
MHz, DMSO-D6): δ (ppm) = 3.26 (s, 3H, CH3), 4.78 - 4.97 (m, 4H, CH2CH2F), 7.63 (dd, 
J = 8.7/2.0 Hz, 1H, 2-H), 7.89 (d, J = 8.8 Hz, 1H, 1-H), 7.92 - 7.97 (m, 3H, 8-H, 5-Hphth, 
6-Hphth), 7.99 - 8.05 (m, 3H, 7-H, 4-Hphth, 7-Hphth), 8.43 (d, J = 2.0 Hz, 1H, 4-H), 8.78 
(d, J = 1.8 Hz, 1H, 5-H). 13C NMR (151 MHz, DMSO-D6): δ (ppm) = 43.4 (d, J = 19.9 
Hz, 1C, CH2CH2F), 44.4 (1C, CH3), 83.1 (d, J = 163.3 Hz, 1C, CH2F), 110.6 (1C, C-8), 
110.7 (1C, C-1), 120.5 (1C, C-4), 120.5 (1C, C-8), 121.6 (1C, C-4b), 121.9 (1C, C-4a), 
123.4 (2C, C-4phth, C-7phth), 124.5 (1C, C-3), 124.7 (1C, C-7), 126.7 (1C, C-2), 131.6 
(2C, C-3aphth, C-7aphth), 131.7 (1C, C-6), 134.8 (2C, C-5phth, C-6phth), 140.4 (1C, C-9a), 
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143.1 (1C, C-8a), 167.5 (2C, C=O). FTIR (neat): ṽ (cm-1) = 2935 (w, C-H, aliph), 1712 
(s, C=O), 1597 (w, C-C, arom), 1138 (s, SO2). 
 
6.3.14 9-(2-Fluoroethyl)-6-methoxycarabzol-3-ammonium chloride (21·HCl) 
Hydrazine monohydrate (0.36 mL, 7.3 mmol, 3 eq.) was added to a solution of 
phthalimide 19 (0.947 g, 2.4 mmol, 1 eq.) in ethanol 96 % (25 mL). The reaction 
mixture was heated at reflux for 2.25 h. After cooling down to room temperature, the 
solution was filtered, the residue was washed with ethanol 96 % followed by 
evaporation of the solvent. The residue was dissolved in ethyl acetate (100 mL) and 
the organic layer was washed with NaOH solution (1 M, 30 mL), water (30 mL) and 
brine (30 mL). After drying (Na2SO4), the solvent was removed under reduced 
pressure. The residue was dissolved in Et2O, filtered and the product was precipitated 
by the addition of a solution of HCl in Et2O (2 M, 1.2 mL, 2.4 mmol, 1 eq.). The product 
was filtered off, washed with Et2O (10 mL) and dried under reduced pressure. Rf = 0.50 
(cyclohexane/ethyl acetate/dimethylethylamine 3:7:0.2). Grey solid, mp 180 - 210 °C 
(decomposition), yield 0.373 g (52 %). Purity (HPLC): 88.9 % (tR = 14.7 min). 
C15H16ClFN2O (294.8 g/mol). Exact mass (APCI): m/z = 259.1242 (calcd. 259.1241 for 
C15H16FN2O [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 3.87 (s, 3H, OCH3), 
4.59 - 4.91 (m, 4H, CH2CH2F), 7.15 (dd, J = 8.9/2.5 Hz, 1H, 7-H), 7.45 (dd, J = 8.7/2.2 
Hz, 1H, 2-H), 7.59 (d, J = 8.9 Hz, 1H, 8-H), 7.70 (d, J = 8.7 Hz, 1H, 1-H), 7.76 (d, J = 
2.5 Hz, 1H, 5-H), 8.12 (d, J = 2.1 Hz, 1H, 4-H), 10.41 (s, 3H, -NH3+). 13C NMR (151 
MHz, DMSO-D6): δ (ppm) = 43.1 (d, J = 20.0 Hz, 1C, CH2CH2F), 55.7 (1C, OCH3), 
82.6 (d, J = 167.7 Hz, 1C, CH2F), 103.3 (1C, C-5), 110.5 (1C, C-1), 110.8 (1C, C-8), 
114.9 (1C, C-4), 115.9 (1C, C-7), 120.5 (1C, C-2), 121.9 (1C, C-4b), 122.2 (1C, C-4a), 
122.6 (1C, C-3), 135.8 (1C, C-8a), 139.8 (1C, C-9a), 153.7 (1C, C-6). FTIR (neat): ṽ 
(cm-1) = 2858 (w, C-H, aliph), 1562 (w, C-C, arom). 
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6.3.15 9-(2-Fluoroethyl)-6-(methylsulfonyl)carbazol-3-ammonium chloride (22·HCl) 
CH2Cl2 (15 mL) and hydrazine monohydrate (32 µL, 0.65 mmol, 2 eq.) were added to 
a stirred suspension of phthalimide 20 (0.143 g, 0.33 mmol, 1 eq.) in ethanol 96 % 
(3 mL). The mixture was heated at 40 °C for 20 h. After the mixture was cooled down 
to room temperature, phthalhydrazide was removed by filtration and the filtrate was 
concentrated under reduced pressure. The residue was dissolved in ethyl acetate 
(30 mL) and the solution was washed with NaOH solution (1 M, 3 x 10 mL), water 
(10 mL) and brine (10 mL). Drying (Na2SO4) and evaporation of the solvent under 
reduced pressure gave a residue, which was dissolved in THF (10 mL) and precipitated 
with a solution of HCl in Et2O (2 M, 0.16 mL, 0.33 mmol, 1 eq.). After filtration, the 
product was washed with Et2O (3 x 2 mL) and dried under reduced pressure. Rf = 0.33 
(ethyl acetate/dimethylethylamine 10:0.2). Colorless solid, mp 205 - 250 °C 
(decomposition), yield 86 mg (77 %). Purity (HPLC): 98.5 % (tR = 12.5 min). 
C15H16ClFN2O2S (342.8 g/mol). Exact mass (APCI): m/z = 307.0908 (calcd. 307.0911 
for C15H16FN2O2S [M+H+]). 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 3.27 (s, 3H, CH3), 
4.76 - 4.91 (m, 4H, CH2CH2F), 7.56 (dd, J = 8.7/2.1 Hz, 1H, 2-H), 7.85 (d, J = 8.7 Hz, 
1H, 1-H), 7.92 (d, J = 8.7 Hz, 1H, 8-H), 8.02 (dd, J = 8.7/1.8 Hz, 1H, 7-H), 8.31 (d, J = 
1.9 Hz, 1H, 4-H), 8.83 (d, J = 1.9 Hz, 1H, 5-H), 10.34 (s, 3H, -NH3+). 13C NMR (101 
MHz, DMSO-D6): δ (ppm) = 43.4 (d, J = 20.0 Hz, 1C, CH2CH2F), 44.4 (1C, CH3), 82.5 
(d, J = 167.6 Hz, 1C, CH2F), 110.7 (1C, C-8), 111.4 (1C, C-1), 115.2 (1C, C-4), 120.8 
(1C, C-4b), 121.3 (1C, C-5), 121.9 (1C, C-2), 122.2 (1C, C-4a), 124.9 (1C, C-7), 125.0 
(1C, C-3), 131.7 (1C, C-6), 140.0 (1C, C-9a), 143.1 (1C, C-8a). FTIR (neat): ṽ (cm-1) = 





Under N2 atmosphere, N-ethyl-N,N-diisopropylamine (0.11 mL, 0.65 mmol, 3 eq.) and 
COMU® (120 mg, 0.28 mmol, 1.3 eq.) were added to a solution of carboxylic acid 12a 
(75 mg, 0.24 mmol, 1.1 eq.) in dry THF (3 mL). After the reaction mixture was stirred 
at room temperature for 30 min, carbazolamine hydrochloride 21·HCl (64 mg, 
0.22 mmol, 1 eq.) was added and stirring was continued for 23 h. All volatiles were 
removed under reduced pressure and the residue was suspended in ethyl acetate 
(5 mL) and water (5 mL). Afterwards, the suspension was filtered and the residue was 
washed with water (10 mL), ethyl acetate (4 mL), ethanol 96 % (4 mL) and CH2Cl2 
(4 mL). The product was dried under reduced pressure and freeze-dried overnight. 
Rf = 0.44 (cyclohexane/ethyl acetate/formic acid 5:5:0.2). Colorless solid, mp 191 °C, 
yield 39 mg (33 %). Purity (HPLC): 96.9 % (tR = 23.0 min). C26H21BrF2N4O3 
(555.4 g/mol). Exact mass (APCI): m/z = 555.0842 (calcd. 555.0838 for 
C26H2279BrF2N4O3 [M+H+]). 1H NMR (400 MHz, DMSO-D6): δ (ppm) = 2.99 (t, J = 6.9 
Hz, 2H, CH2CH2CONH), 3.36 - 3.38 (m, 2H, CH2CH2CONH), 3.85 (s, 3H, OCH3), 
4.60 - 4.82 (m, 4H, CH2CH2F), 7.07 (dd, J = 8.8/2.5 Hz, 1H, 7-Hcarb), 7.42 - 7.48 (m, 
2H, 2-Hcarb, 5-Hphenyl), 7.49 - 7.52 (m, 2H, 1-Hcarb, 8-Hcarb), 7.58 (d, J = 2.4 Hz, 1H, 5-
Hcarb), 7.83 (dd, J = 8.6/2.6 Hz, 1H, 3-Hphenyl), 7.89 (dd, J = 8.8/6.1 Hz, 1H, 6-Hphenyl), 
8.43 (d, J = 1.7 Hz, 1H, 4-Hcarb), 10.12 (s, 1H, CONH). 13C NMR (101 MHz, DMSO-
D6): δ (ppm) = 21.8 (1C, CH2CH2CONH), 31.9 (1C, CH2CH2CONH), 43.0 (d, J = 20.2 
Hz, 1C, CH2CH2F), 55.6 (1C, OCH3), 82.6 (d, J = 167.8 Hz, 1C, CH2F), 102.7 (1C, C-
5carb), 109.4 (1C, C-1carb), 110.4 (1C, C-8carb), 111.1 (1C, C-4carb), 115.0 (1C, C-7carb), 
115.5 (d, J = 21.6 Hz, 1C, C-5phenyl), 118.8 (1C, C-2carb), 121.4 (d, J = 25.0 Hz, 1C, C-
3phenyl), 121.7 (1C, C-4acarb), 122.1 (d, J = 10.0 Hz, 1C, C-2phenyl), 122.4 (1C, C-4bcarb), 
124.4 (d, J = 3.4 Hz, 1C, C-1phenyl), 130.8 (1C, C-3carb), 133.6 (d, J = 9.4 Hz, 1C, C-
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6phenyl), 135.6 (1C, C-8acarb), 137.3 (1C, C-9acarb), 153.2 (1C, C-6carb), 162.8 (d, J = 
253.3 Hz, 1C, C-4phenyl), 166.5 (1C, C-3oxadiazole), 168.5 (1C, C=O), 179.6 (1C, C-




Under N2 atmosphere, N-ethyl-N,N-diisopropylamine (91 µL, 0.53 mmol, 3 eq.) and 
COMU® (98 mg, 0.23 mmol, 1.3 eq.) were added to a solution of carboxylic acid 12a 
(61 mg, 0.19 mmol, 1.1 eq.) in dry THF (8 mL). After the reaction mixture was stirred 
at room temperature for 30 min, carbazolamine hydrochloride 22·HCl (60 mg, 
0.18 mmol, 1 eq.) was added and stirring was continued for 20 h. Afterwards, all 
volatiles were removed under reduced pressure and the residue was dissolved in ethyl 
acetate (30 mL). The organic layer was washed with NaOH solution (10 mL), water 
(2 x 10 mL) and brine (10 mL), dried (Na2SO4) and concentrated in vacuo. The residue 
was purified by fc with a gradient (∅ = 2 cm, l = 15 cm, v = 10 mL, cyclohexane/CH2Cl2 
40:60, 20:80, 0:100, CH2Cl2/methanol 100:0.5, 100:0.75, 100:1, Rf = 0.29 
(cyclohexane/ethyl acetate/formic acid 4:6:0.2)). Colorless solid, mp 212 - 213 °C, 
yield 49 mg (47 %). Purity (HPLC): 97.6 % (tR = 21.1 min). C26H21BrF2N4O4S 
(603.4 g/mol). Exact mass (APCI): m/z = 603.0508 (calcd. 603.0508 for 
C26H2279BrF2N4O4S [M+H+]). 1H NMR (600 MHz, DMSO-D6): δ (ppm) = 3.02 (t, J = 7.0 
Hz, 2H, CH2CH2CONH), 3.25 (s, 3H, CH3), 3.36 (t, J = 7.0 Hz, 2H, CH2CH2CONH), 
4.74 - 4.85 (m, 4H, CH2CH2F), 7.45 (td, J = 8.5/2.6 Hz, 1H, 5-Hphenyl), 7.60 (dd, J = 
8.8/1.8 Hz, 1H, 2-Hcarb), 7.69 (d, J = 8.8 Hz, 1H, 1-Hcarb), 7.80 - 7.86 (m, 2H, 8-Hcarb, 3-
Hphenyl), 7.89 (dd, J = 8.7/6.1 Hz, 1H, 6-Hphenyl), 7.95 (dd, J = 8.7/1.7 Hz, 1H, 7-Hcarb), 
8.61 (d, J = 1.8 Hz, 1H, 4-Hcarb), 8.65 (d, J = 1.7 Hz, 1H, 5-Hcarb), 10.25 (s, 1H, CONH). 
13C NMR (151 MHz, DMSO-D6): δ (ppm) = 21.8 (1C, CH2CH2CONH), 32.0 (1C, 
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CH2CH2CONH), 43.3 (d, J = 19.9 Hz, 1C, CH2CH2F), 44.4 (1C, CH3), 82.5 (d, J = 167.7 
Hz, 1C, CH2F), 110.2 (1C, C-8carb), 110.4 (1C, C-1carb), 111.2 (1C, C-4carb), 115.5 (d, J 
= 21.6 Hz, 1C, C-5phenyl), 119.9 (1C, C-2carb), 120.1 (1C, C-5carb), 121.4 (d, J = 25.0 Hz, 
1C, C-3phenyl), 121.7 (1C, C-4acarb), 121.8 (1C, C-4bcarb), 122.1 (d, J = 10.1 Hz, 1C, C-
2phenyl), 124.1 (1C, C-7carb), 124.4 (d, J = 3.4 Hz, 1C, C-1phenyl), 131.0 (1C, C-6carb), 
132.5 (1C, C-3carb), 133.6 (d, J = 9.4 Hz, 1C, C-6phenyl), 137.5 (1C, C-9a carb), 142.9 (1C, 
C-8acarb), 162.8 (d, J = 253.2 Hz, 1C, C-4phenyl), 166.5 (1C, C-3oxadiazole), 168.8 (1C, 
C=O), 179.6 (1C, C-5oxadiazole). FTIR (neat): ṽ (cm-1) = 3325 (w, N-H), 2924 (w, C-H, 




Hydrazine monohydrate (66 µL, 1.4 mmol, 2 eq.) was added to a solution of 
phthalimide 17 (268 mg, 0.68 mmol, 1 eq.) in ethanol 96 % (10 mL). The reaction 
mixture was heated at reflux for 2 h. After evaporation of the solvent, the residue was 
dissolved in ethyl acetate (30 mL) and the organic layer was washed with NaOH 
solution (1 M, 20 mL). The NaOH solution was extracted with ethyl acetate (2 x 20 mL). 
The combined organic layers were washed with water (20 mL) and brine (20 ml), dried 
(Na2SO4) and concentrated under reduced pressure. The residue was dissolved in 
Et2O and filtered followed by the addition of a solution of HCl in Et2O (2 M, 0.34 mL, 
0.68 mmol, 1.0 eq) until the salt 25·HCl precipitated completely. The product was 
filtered off, washed with Et2O (5 mL) and dried under reduced pressure. Rf = 0.35 (ethyl 
acetate/methanol/dimethylethylamine 7:3:0.2). Beige solid, mp 225 - 226 °C, yield 
122 mg (60 %). Purity (HPLC): 96.6 % (tR = 14.2 min). C15H20ClFN2O (298.8 g/mol). 
Exact mass (APCI): m/z = 363.1555 (calcd. 263.1554 for C15H20FN2O [M+H+]). 1H NMR 
(400 MHz, DMSO-D6): δ (ppm) = 1.86 - 1.99 (m, 1H, 2-H), 2.16 - 2.26 (m, 1H, 2-H), 
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2.66 (dd, J = 14.8/8.6 Hz, 1H, 4-H), 2.73 - 2.93 (m, 2H, 1-CH2), 3.03 (dd, J = 16.6/3.3 
Hz, 1H, 4-H), 3.47 (s, broad, 1H, 3-H), 3.74 (s, 3H, OCH3), 4.33 (dt, J = 28.0/4.6 Hz, 
2H, CH2CH2F), 4.61 (dt, J = 47.7/4.3 Hz, 2H, CH2F), 6.71 (dd, J = 8.7/2.0 Hz, 1H, 7-
H), 6.87 (d, J = 2.0 Hz, 1H, 5-H), 7.29 (d, J = 8.8 Hz, 1H, 8-H), 8.30 (s, 3H, -NH3+). 13C 
NMR (101 MHz, DMSO-D6): δ (ppm) = 19.6 (1C, C-1), 25.7 (1C, C-4), 26.6 (1C, C-2), 
43.0 (d, J = 20.4 Hz, 1C, CH2CH2F), 46.9 (1C, C-3), 55.4 (1C, OCH3), 82.9 (d, J = 
167.5 Hz, 1C, CH2F), 99.8 (1C, C-5), 104.7 (1C, C-4a), 110.2 (1C, C-8), 110.3 (1C, C-
7), 126.7 (1C, C-4b), 131.7 (1C, C-8a), 134.9 (1C, C-9a), 153.5 (1C, C-6). FTIR (neat): 




Under N2 atmosphere, N-ethyl-N,N-diisopropylamine (0.13 mL, 0.74 mmol, 3 eq.) and 
COMU® (137 mg, 0.32 mmol, 1.3 eq.) were added to a solution of carboxylic acid 12a 
(85 mg, 0.27 mmol, 1.1 eq.) in dry THF (3 mL). After the reaction mixture was stirred 
at room temperature for 30 min, tetrahydrocarbazolamine hydrochloride 25·HCl 
(74 mg, 0.25 mmol, 1 eq.) was added and stirring was continued for 23 h. Afterwards, 
all volatiles were removed under reduced pressure and the residue was dissolved in 
ethyl acetate (30 mL). The organic layer was washed with water (2 x 10 mL) and brine 
(10 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by fc 
(∅ = 2 cm, l = 15 cm, v = 10 mL, cyclohexane/ethyl acetate 70:30, Rf = 0.38 
(cyclohexane/ethyl acetate/formic acid 5:5:0.2)). Colorless solid, mp 159 °C, yield 
91 mg (66 %). Purity (HPLC): 93.0 % (tR = 22.7 min). C26H25BrF2N4O3 (559.4 g/mol). 
Exact mass (APCI): m/z = 559.1152 (calcd. 559.1151 for C26H2679BrF2N4O3 [M+H+]). 
1H NMR (400 MHz, DMSO-D6): δ (ppm) = 1.73 - 1.85 (m, 1H, 2-Hcarb), 1.94 - 2.03 (m, 
1H, 2-Hcarb), 2.40 - 2.48 (m, 1H, 4-Hcarb), 2.72 (t, J = 7.4 Hz, 2H, CH2CH2CONH), 2.74 
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- 2.86 (m, 2H, 1-CH2carb), 2.90 (dd, J = 15.0/5.2 Hz, 1H, 4-Hcarb), 3.24 (t, J = 7.1 Hz, 
2H, CH2CH2CONH), 3.74 (s, 3H, OCH3), 4.04 (dt, J = 12.0/7.2 Hz, 1H, 3-Hcarb), 4.32 
(dt, J = 27.8/4.1 Hz, 2H, CH2CH2F), 4.62 (dt, J = 47.5/4.7 Hz, 2H, CH2F), 6.70 (dd, J = 
8.8/2.5 Hz, 1H, 7-Hcarb), 6.83 (d, J = 2.4 Hz, 1H, 5-Hcarb), 7.27 (d, J = 8.8 Hz, 1H, 8-
Hcarb), 7.46 (td, J = 8.4/2.6 Hz, 1H, 5-Hphenyl), 7.84 (dd, J = 8.6/2.6 Hz, 1H, 3-Hphenyl), 
7.88 (dd, J = 8.7/6.1 Hz, 1H, 6-Hphenyl), 8.15 (d, J = 7.6 Hz, 1H, CONH). 13C NMR (101 
MHz, DMSO-D6): δ (ppm) = 20.0 (1C, C-1carb), 21.9 (1C, CH2CH2CONH), 27.3 (1C, C-
4carb), 28.4 (1C, C-2carb), 31.2 (1C, CH2CH2CONH), 42.9 (d, J = 20.4 Hz, 1C, 
CH2CH2F), 45.1 (1C, C-3carb), 55.4 (1C, OCH3), 82.9 (d, J = 167.6 Hz, 1C, CH2CH2F), 
99.8 (1C, C-5carb), 106.4 (1C, C-4acarb), 109.9 (2C, C-7carb, C-8carb), 115.5 (d, J = 21.6 
Hz, 1C, C-5phenyl), 121.4 (d, J = 25.1 Hz, 1C, C-3phenyl), 122.1 (d, J = 10.1 Hz, 1C, C-
2phenyl), 124.5 (d, J = 3.5 Hz, 1C, C-1phenyl), 127.1 (1C, C-4bcarb), 131.6 (1C, C-8acarb), 
133.6 (d, J = 9.4 Hz, 1C, C-6phenyl), 135.3 (1C, C-9acarb), 153.3 (1C, C-6carb), 162.8 (d, 
J = 253.3 Hz, 1C, C-4phenyl), 166.5 (1C, C-3oxadiazole), 169.4 (1C, C=O), 179,6 (1C, C-
5oxadiazole). FTIR (neat): ṽ (cm-1) = 3302 (w, N-H), 2931 (w, C-H, aliph), 1635 (s, C=O). 
 
6.4 Receptor binding studies 
[3H]CP55940 displacement assays were used for the determination of affinity (Ki) 
values of ligands for the cannabinoid CB1 and CB2 receptors. Membrane aliquots 
containing 5 μg (CHOK1hCB1_bgal) or 1 μg (CHOK1hCB2_bgal) of membrane protein 
in 100 μL assay buffer (50 mM Tris–HCl, 5 mM MgCl2, 0.1 % BSA, pH 7.4) were 
incubated at 30 °C for 1 h, in presence of 3.5 nM [3H]CP55940 (CHOK1hCB1_bgal) or 
1.5 nM [3H]CP55940 (CHOK1hCB2_bgal). Initially, 1 µM of competing ligand was 
used, followed by six concentrations of competing ligand (between 10-5.5 M and 10-
10.5 M) when more than 50 % displacement was found at 1 µM. Non-specific binding 
was determined in the presence of 10 μM AM630 (CHOK1hCB2_bgal) or 10 μM 
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SR141716A (CHOK1hCB1_bgal). Incubation was terminated by rapid filtration through 
GF/C filters (Whatman International, Maidstone, UK), and followed by extensive 
washing using a Filtermate 96-well harvester (Perkin Elmer, Groningen, The 
Netherlands). Filter-bound radioactivity was determined by scintillation spectrometry 
using a 1450 Microbeta Wallac Trilux scintillation counter (Perkin Elmer).  
Data analysis was performed by using the nonlinear regression curve fitting program 
GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA). From displacement 
assays, IC50 values were obtained by non-linear regression analysis of the 
displacement curves. The obtained IC50 values were converted into Ki values using the 
Cheng Prusoff equation [26] to determine the affinity of the ligands using a KD value of 
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